About admin

This author has not yet filled in any details.
So far admin has created 39 blog entries.

20 Years Later: A Cancer DNA Load Blood Test

Chronix Biomedical

Chronix Biomedical filed its first patent application 20 years ago on October 4, 1996. This first patent application has subsequently led to a series of exciting developments culminating in revolutionary genetic testing technology to diagnose...

By |2019-03-21T09:38:02+00:00October 4th, 2016|Chronix news|0 Comments

Chronix Biomedical welcomes moves to define new regulatory standards in liquid biopsy field

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (20 July 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, welcomes the recent moves to more clearly define US regulatory standards for the use of...

By |2019-03-21T09:38:02+00:00July 20th, 2016|Chronix news|0 Comments

Cell Free DNA accurately correlates with breast cancer DNA

Howard B. Urnovitz, Modulation of breast cancer cell-free DNA with surgical resection. J Clin Oncol 31, 2013 (suppl; abstr 11060)

Researchers from Chronix Biomedical and The University of Texas MD Anderson Cancer Center announced results from a pilot study demonstrating the utility of cell-free DNA (cfDNA) blood tests as a companion diagnostic for breast cancer patients at the American Society of Clinical Oncology Annual Meeting (ASCO 2013).

By |2019-03-21T09:38:03+00:00July 3rd, 2016|Other publications|0 Comments

Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis

Chronix Biomedical

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...

By |2019-03-21T09:38:03+00:00June 3rd, 2016|Chronix news|0 Comments

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...

By |2019-03-21T09:38:03+00:00June 1st, 2016|Chronix news|0 Comments

Detection of novel HPV mutations and chromosomal number imbalance

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...

By |2019-03-21T09:38:03+00:00June 1st, 2016|Other publications|0 Comments

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to immunotherapy at the ASCO Annual Meeting

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number...

By |2019-03-21T09:38:04+00:00May 3rd, 2016|Chronix news|0 Comments

Clinica Highlights Chronix Biomedical’s Diagnostics

Tina Tan, Chronix’s new liquid biopsy approach show promise as early predictor of cancer therapies. Clinica, 18 April 2016.

A blood-based test which looks at chromosomal gains and losses in cell-free DNA (cfDNA) has demonstrated its potential of being a predictor of how well cancer patients are responding to chemotherapy.

By |2018-08-24T09:34:01+00:00April 18th, 2016|Other publications|0 Comments